Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05216042
Other study ID # IRB-300008758
Secondary ID R01HL163081
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2022
Est. completion date April 30, 2027

Study information

Verified date March 2024
Source University of Alabama at Birmingham
Contact Nehal Vekariya, MS
Phone 205-934-7173
Email nvekariya@uabmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have ~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have ~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.


Description:

The heart plays an endocrine role by secreting hormones called Natriuretic Peptides (NPs). NPs directly regulates blood pressure (BP) by causing dilation of blood vessels and removing sodium and water from the body. Apart from blood pressure regulation, previous experimental data suggest that NPs has a wide range of favorable metabolic effects and regulates energy homeostasis, fatty acid oxidation, lipid metabolism, glucose intolerance, insulin sensitivity, and obesity. Investigators have demonstrated that low levels of NPs can increase the risk of developing cardiovascular (CV) events (such as heart failure [HF], stroke, myocardial infarction [MI], or heart attack). Former studies by the investigators have shown that the NP deficient states such as obese and black individuals contributes to lower energy expenditure, poor metabolic profile and promotes the onset of diabetes. Certain genetic factors contribute to the higher predisposition to cardiometabolic disease in individuals with relative atrial natriuretic peptide (ANP) deficiency. PI and others have identified a common genetic variant, rs5068 is associated with higher plasma ANP levels. The lack of the rs5068 variant has a comparable effect on ANP levels as seen in obese and black individuals and plays a causal role in cardiometabolic health regulation. The rs5068 variant is only present in 10-12% of the population, thereby leaving nearly 90% of adults vulnerable to the potential adverse cardiometabolic impact of having a relative ANP deficiency. This indicates that a low ANP genotype is associated with a poor metabolic health profile. Our earlier study, in normotensive healthy young adults, demonstrated that a high glucose meal results in reduce ANP levels by 20-30%, which indicates that ANP is a glucose-responsive hormone. The preliminary data from our ongoing clinical trial has shown increased ANP levels with response to the exercise. The impact of genetically determined low ANP levels on the differences in exercise-induced ANP (beneficial) increase and glucose load-induced suppression of ANP (detrimental) is not known in humans. Micro-RNA-425 (miR-425) is a negative regulator of ANP and acts in a genotype-specific manner. In our previous study, the investigators have demonstrated that miR-425 levels decreased by 71% following one week on a high-salt diet compared with a low-salt diet in individuals with low ANP genotype, and no change was seen in high ANP genotype individuals. In vitro experiments in animals showed an increase in cardiac miR-425 levels by 22-30%. The negative regulator of ANP also independently negatively regulates the control of energy expenditure. The responsiveness of mir-425 to glucose challenge and exercise challenge (metabolic perturbations) has not been previously evaluated in humans. Individuals with genetically reduced amounts of ANP will be the focus of our present genotype-guided physiological investigation. Following the glucose and exercise challenges, the investigators will additionally investigate the extent to which miR-425 mediated control of ANP suppression occurs. This study will help in understanding how ANP regulates cardiometabolic health in individuals with genetically lower ANP levels.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date April 30, 2027
Est. primary completion date April 30, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults: Age more than or equal to 18; an equal number of Males and Females - Consent to the collection of genetic material - Willing to adhere to the study protocol Exclusion Criteria: - Age <18, at screening. - BMI >45 kg/m2. - Blood pressure more than 140/90 mmHg. - Participants who are taking more than 2 hypertension medications. - History of diabetes or fasting plasma glucose >126 mg/dl or HbA1C>=6.5% or prior treatment with antidiabetic medication. - Have any past or present history of cardiovascular diseases (stroke, seizure, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia) - Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence); - Estimated GFR < 60 ml/min/1.73 m2; albumin creatinine ratio =30 mg/g - Hepatic Transaminase (AST and ALT) levels >3x the upper limit of normal - Anemia (men, Hct < 38%; women, Hct <36%) - Inability to exercise on a treadmill

Study Design


Intervention

Dietary Supplement:
Study diet
Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)
Other:
Exercise capacity VO2 max determination
Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
Exercise Challenge
Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
Glucose Challenge
Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (2)

Lead Sponsor Collaborator
University of Alabama at Birmingham National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (5)

Arora P, Reingold J, Baggish A, Guanaga DP, Wu C, Ghorbani A, Song Y, Chen-Tournaux A, Khan AM, Tainsh LT, Buys ES, Williams JS, Heublein DM, Burnett JC, Semigran MJ, Bloch KD, Scherrer-Crosbie M, Newton-Cheh C, Kaplan LM, Wang TJ. Weight loss, saline loading, and the natriuretic peptide system. J Am Heart Assoc. 2015 Jan 16;4(1):e001265. doi: 10.1161/JAHA.114.001265. — View Citation

Arora P, Wu C, Hamid T, Arora G, Agha O, Allen K, Tainsh RET, Hu D, Ryan RA, Domian IJ, Buys ES, Bloch DB, Prabhu SD, Bloch KD, Newton-Cheh C, Wang TJ. Acute Metabolic Influences on the Natriuretic Peptide System in Humans. J Am Coll Cardiol. 2016 Feb 23;67(7):804-812. doi: 10.1016/j.jacc.2015.11.049. — View Citation

Bajaj NS, Gutierrez OM, Arora G, Judd SE, Patel N, Bennett A, Prabhu SD, Howard G, Howard VJ, Cushman M, Arora P. Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. JAMA Cardiol. 2018 Jan 1;3(1):11-17. doi: 10.1001/jamacardio.2017.4207. — View Citation

Parcha V, Kalra R, Li P, Oparil S, Arora G, Arora P. Nocturnal blood pressure dipping in treated hypertensives: insights from the SPRINT trial. Eur J Prev Cardiol. 2022 Feb 19;29(1):e25-e28. doi: 10.1093/eurjpc/zwaa125. No abstract available. — View Citation

Parcha V, Patel N, Gutierrez OM, Li P, Gamble KL, Musunuru K, Margulies KB, Cappola TP, Wang TJ, Arora G, Arora P. Chronobiology of Natriuretic Peptides and Blood Pressure in Lean and Obese Individuals. J Am Coll Cardiol. 2021 May 11;77(18):2291-2303. doi: 10.1016/j.jacc.2021.03.291. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in MRproANP levels following a standardized oral glucose challenge between the high genotype group and low genotype group. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Primary Change in Exercise Energy Expenditure between the high genotype and low genotype group. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Primary Change in miR-425 levels following a standardized oral glucose challenge in those with low ANP genotype. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Primary Change in miR-425 levels following a standardized exercise challenge in those with low ANP genotype. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in the NPs (ANP, BNP, NTproBNP) following the glucose challenge between the high genotype group and low genotype group. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Secondary Change in the serum glucose following the glucose challenge between the high genotype group and low genotype group. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Secondary Change in the serum insulin following the glucose challenge between the high genotype group and low genotype group. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Secondary Change in Resting Energy Expenditure (REE) between the two genotype groups. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in the NPs (ANP, BNP, NTproBNP) with standardized exercise protocol between the two genotype groups. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in the serum glucose levels with standardized exercise protocol between the two genotype groups. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in the serum insulin levels with standardized exercise protocol between the two genotype groups. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in the free fatty acid levels with standardized exercise protocol between the two genotype groups. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in the glycerol levels with standardized exercise protocol between the two genotype groups. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following glucose challenge. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Secondary Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following exercise challenge. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in miR-425 levels with change in serum glucose levels following glucose challenge. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Secondary Change in miR-425 levels with change in serum insulin levels following glucose challenge. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Secondary Change in miR-425 levels with change in serum glucose levels following exercise challenge. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in miR-425 levels with change in serum insulin levels following exercise challenge. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Correlation of resting miR-425 levels with REE Levels of miR-425 measured in 2-??CT will be assessed and will be related to REE measured in kcal/min About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following glucose challenge between the two genotype groups. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Secondary Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following exercise challenge between the two genotype groups. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in miR-425 levels with change in serum glucose levels following glucose challenge between the two genotype groups. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Secondary Change in miR-425 levels with change in serum insulin levels following glucose challenge between the two genotype groups. From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days
Secondary Change in miR-425 levels with change in serum glucose levels following exercise challenge between the two genotype groups. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Change in miR-425 levels with change in serum insulin levels following exercise challenge between the two genotype groups. About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
Secondary Correlation of resting miR-425 levels with REE between the genotype groups. Levels of miR-425 levels measured in 2-??CT will be related to the REE measured in kcal/min and will be compared between the genotype groups About 3 hours on the exercise challenge visit day after consuming study meals for 4 days
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2